Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Qichen Zhang, Peng Xie, Xiaoming Hou, Chengpeng Zhao, Ling Duan & Hui Qiao. Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report. Journal of Chemotherapy 0:0, pages 1-9.
Read now
Read now
Articles from other publishers (25)
Mostafa A. Mansour, Asmaa M. AboulMagd, Samar H. Abbas, Hamdy M. Abdel-Rahman & Mohamed Abdel-Aziz. (2023) Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review. RSC Advances 13:27, pages 18825-18853.
Crossref
Crossref
Liping Fu, Yu Cao, Jingbai Chen, Ruoyu He, Yanmei Zhao, Yaping Zhao, Jianjun Xi, Rangxiao Zhuang & Chongmei Tian. (2023) Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing dihydroquinoxalinone as novel EGFRL858R/T790M kinase inhibitors against non-small-cell lung cancer. Medicinal Chemistry Research 32:6, pages 1130-1142.
Crossref
Crossref
Saqib Raza Khan, Matthias Scheffler, Salman Muhammad Soomar, Yasmin Abdul Rashid, Munira Moosajee, Aamir Ahmad, Afsheen Raza & Shahab Uddin. (2023) Role of circulating-tumor DNA in the early-stage non-small cell lung carcinoma as a predictive biomarker. Pathology - Research and Practice 245, pages 154455.
Crossref
Crossref
Yuhao Fu, Ying Li, Yinling Ma, Xueru He, Xuejiao Xun, Yanjun Cui, Liju Fan & Zhanjun Dong. (2022) Effects of voriconazole and fluconazole on the pharmacokinetics of almonertinib in rats by UPLC–MS/MS. Biomedical Chromatography 37:1.
Crossref
Crossref
Kai Fu, Fachao Xie, Fang Wang & Liwu Fu. (2022) Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Aziz Unnisa, Ananda Kumar Chettupalli, Talib Hussain & Mohammad Amjad Kamal. (2022) Recent Advances in Epidermal Growth Factor Receptor Inhibitors (EGFRIs) and
their Role in the Treatment of Cancer: A Review. Anti-Cancer Agents in Medicinal Chemistry 22:20, pages 3370-3381.
Crossref
Crossref
Khalid Saad Alharbi, Mohammad Arshad Javed Shaikh, Obaid Afzal, Abdulmalik Saleh Alfawaz Altamimi, Waleed Hassan Almalki, Sami I. Alzarea, Imran Kazmi, Fahad A. Al-Abbasi, Sachin Kumar Singh, Kamal Dua & Gaurav Gupta. (2022) An overview of epithelial growth factor receptor (EGFR) inhibitors in cancer therapy. Chemico-Biological Interactions 366, pages 110108.
Crossref
Crossref
Tingting Hu, Hanlin Gong, Jiayue Xu, Yuan Huang, Fengbo Wu & Zhiyao He. (2022) Nanomedicines for Overcoming Cancer Drug Resistance. Pharmaceutics 14:8, pages 1606.
Crossref
Crossref
Guangzhi Ma, Yunfu Deng, Luxi Qian, Karin A. Vallega, Guojing Zhang, Xingming Deng, Taofeek K. Owonikoko, Suresh S. Ramalingam, Douglas D. Fang, Yifan Zhai & Shi-Yong Sun. (2022) Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both. Oncogene 41:12, pages 1691-1700.
Crossref
Crossref
Bhupender Nehra, Bijo Mathew & Pooja A. Chawla. (2022) A Medicinal Chemist’s Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents. Current Topics in Medicinal Chemistry 22:6, pages 493-528.
Crossref
Crossref
Julien Ancel, Maxime Dewolf, Gaëtan Deslée, Béatrice Nawrocky-Raby, Véronique Dalstein, Christine Gilles & Myriam Polette. (2022) Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions. Cells Tissues Organs 211:2, pages 91-109.
Crossref
Crossref
Bharti Sharma, Vikram Jeet Singh & Pooja A. Chawla. (2021) Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress. Bioorganic Chemistry 116, pages 105393.
Crossref
Crossref
Guoqing Qian, Jianping Guo, Karin A. Vallega, Changjiang Hu, Zhen Chen, Yunfu Deng, Qiming Wang, Songqing Fan, Suresh S. Ramalingam, Taofeek K. Owonikoko, Wenyi Wei & Shi-Yong Sun. (2021) Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors. Molecular Cancer Research 19:10, pages 1622-1634.
Crossref
Crossref
Wen Zhao, Danlei Yu, Zhen Chen, Weilong Yao, Jin Yang, Suresh S. Ramalingam & Shi-Yong Sun. (2021) Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis. Cancer Letters 519, pages 141-149.
Crossref
Crossref
Jing Zhu, Qian Yang & Weiguo Xu. (2021) Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective. Pharmaceutics 13:9, pages 1500.
Crossref
Crossref
Zhenzhen Ying, Jingyao Wei, Ruijuan Liu, Fang Zhao, Yifang Yu & Xin Tian. (2020) An UPLC-MS/MS Method for Determination of Osimertinib in Rat Plasma: Application to Investigating the Effect of Ginsenoside Rg3 on the Pharmacokinetics of Osimertinib. International Journal of Analytical Chemistry 2020, pages 1-9.
Crossref
Crossref
Sinead Toomey, Aoife Carr, Mateusz Janusz Mezynski, Yasir Elamin, Shereen Rafee, Mattia Cremona, Clare Morgan, Stephen Madden, Khairun I. Abdul-Jalil, Kathy Gately, Angela Farrelly, Elaine W. Kay, Susan Kennedy, Kenneth O’Byrne, Liam Grogan, Oscar Breathnach, Patrick G. Morris, Alexander J. Eustace, Joanna Fay, Robert Cummins, Anthony O’Grady, Roshni Kalachand, Norma O’Donovan, Fergal Kelleher, Aine O’Reilly, Mark Doherty, John Crown & Bryan T. Hennessy. (2020) Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. Journal of Translational Medicine 18:1.
Crossref
Crossref
Jennifer W. Carlisle, Conor E. Steuer, Taofeek K. Owonikoko & Nabil F. Saba. (2020) An update on the immune landscape in lung and head and neck cancers. CA: A Cancer Journal for Clinicians 70:6, pages 505-517.
Crossref
Crossref
Jiaan Shao, Shuangrong Liu, Xingyu Liu, Youlu Pan & Wenteng Chen. (2020) Design, synthesis and SAR study of 2-aminopyrimidines with diverse Michael addition acceptors for chemically tuning the potency against EGFRL858R/T790M. Bioorganic & Medicinal Chemistry 28:19, pages 115680.
Crossref
Crossref
Fei Chen, Naifei Chen, Yu Yu & Jiuwei Cui. (2020) Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis. Frontiers in Oncology 10.
Crossref
Crossref
Adileh Ayati, Setareh Moghimi, Somayeh Salarinejad, Maliheh Safavi, Behjat Pouramiri & Alireza Foroumadi. (2020) A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorganic Chemistry 99, pages 103811.
Crossref
Crossref
Xiu Hu, Zuo-yan Zhang, Lin-wen Wu, Ling-hui Zeng, Hui Chen, Hua-jian Zhu, Jian-kang Zhang, Jiaan Shao, Chong Zhang, Yang-ling Li & Neng-ming Lin. (2020) A natural anthraquinone derivative shikonin synergizes with AZD9291 against wtEGFR NSCLC cells through reactive oxygen species-mediated endoplasmic reticulum stress. Phytomedicine 68, pages 153189.
Crossref
Crossref
Alessandro Gambella, Rebecca Senetta, Giammarco Collemi, Stefano Gabriele Vallero, Matteo Monticelli, Fabio Cofano, Pietro Zeppa, Diego Garbossa, Alessia Pellerino, Roberta Rudà, Riccardo Soffietti, Franca Fagioli, Mauro Papotti, Paola Cassoni & Luca Bertero. (2020) NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target. International Journal of Molecular Sciences 21:3, pages 753.
Crossref
Crossref
Juan C. Falla-Martinez, Daniela Espinosa, Juan C. Baena, Lisa X. Rodriguez, Luz F. Sua & Angela R. Zambrano. (2019) An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report. Journal of Medical Case Reports 13:1.
Crossref
Crossref
Kaja Karaś, Anna Sałkowska, Iwona Karwaciak, Aurelia Walczak-Drzewiecka, Jarosław Dastych, Rafał A. Bachorz & Marcin Ratajewski. (2019) The Dichotomous Nature of AZ5104 (an EGFR Inhibitor) Towards RORγ and RORγT. International Journal of Molecular Sciences 20:22, pages 5780.
Crossref
Crossref